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The standard deviation of units-per-day over the year was used
as the proxy measure of non-adherence. Total and diabetes-
attributable costs were computed including insurance payments
and patients’ co-payments. Multivariate log-linear regressions
were estimated for costs using variability in long/intermediate-
acting insulin, diabetes severity, overall comorbidity burden, hos-
pitalization in prior six-months, insulin pump use, concomitant
use of short-acting insulin, oral antidiabetic medications, patient
initiating antidiabetic therapy, insurance plan, and demographic
variables. RESULTS: A total of 11,125 patients had at least three
prescriptions for long-acting or intermediate-acting insulin and
were used in the models. The standard deviation of units-per-day
ranged from zero to 210, with a median of 11 and 20th and 80th
percentiles of ﬁve and 23, respectively. Total costs increased
0.39% and diabetes-attributable costs increased 0.31% for each
unit increase in the standard deviation of insulin units-per-day.
CONCLUSIONS: Increased variability of insulin use increases
total and diabetes-attributable annual costs.
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Electronic medical records (EMR) have been incorporated into
many health care settings to assist physicians in sharing patient
information effectively across health care providers. Most EMRs
were designed to optimize sharing of clinical information and
not to accommodate the needs of health services researchers.
Building a comprehensive database that includes information
from multiple databases and EMR sources can be challenging.
OBJECTIVE: To develop a comprehensive diabetes dataset of
clinical resource utilization information and costs using a com-
munity clinics and hospital based EMR and charge data. This
allows a direct comparison of resource utilization and econom-
ics associated with various anti-diabetic treatments. METHODS:
Prescription order data for patients on anti-diabetic medications
or with a diagnosis of diabetes in 2001–2003 were obtained from
the community clinics EMR system. Other health care informa-
tion was collected from the hospital outpatient clinics and hos-
pital EMR systems. Pertinent health care information included
site of care, procedures performed, laboratory tests results, and
diagnosis. Missing information was retrieved manually from the
EMR chart from physician notes which are not transferred to
the EMR database or imputed from retrieved data sources.
Resource use information was matched to ﬁnancial data based
on patient visit numbers. Professional charges were matched to
each visit based on patient identiﬁer and approximate visitation
date, with Institutional Review Board approval. RESULTS: The
ﬁnal dataset includes pertinent clinical, costs resource utilization
information for patients suffering from diabetes across 810
patients receiving insulin. This dataset was used to determine the
differences in resources and cost differences between different
insulin regimens. CONCLUSION: Integrated data systems
across outpatient and inpatient settings can be very useful in out-
comes research however pulling together information from
various datasets can be challenging.
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OBJECTIVES: The Diabetes Prevention Program (DPP)
excluded subjects at baseline due to multiple disease states. The
objectives of this study were to 1) design a long-term cost-
effectiveness model to evaluate the use of intensive lifestyle inter-
vention to prevent type-2 diabetes (T2DM) based on the DPP
study design; and 2) attempt to project these ﬁndings onto a
more generalized hypothetical population than that studied by
the DPP. METHODS: Markov models were developed based on
the DPP results incorporating the states of normal glucose tol-
erance, impaired glucose tolerance, T2DM and death. Transition
probabilities were derived from DPP and current literature. 
A three-year intervention was assumed with outcomes of 1) a 
three-year duration of effect; and 2) a lifetime duration of effect.
A second set of models, based on a hypothetical, more general-
ized population included higher direct medical control cost of
illness, and US Life Table mortality ﬁgures. RESULTS: Lifestyle
dominated placebo in both models, with the following results
derived for incremental cost-effectiveness ratios: 1) DPP model—
3-year duration = -$6,319/LY; 2) DPP model—lifetime duration
= -$11,804/LY; 3) generalized model—three-year duration =
-$16,064/LY; and 4) generalized model—lifetime duration =
-$19,496/LY. A maximal acceptable cost of intervention per year
for the three-year duration of effect that could be used to main-
tain lifestyle domination was also established. These values were:
1) DPP model—three-year duration = $1820/year; 2) DPP
model—lifetime duration = $6500/year; 3) generalized model—
three-year duration = $2910, and 4) generalized model—lifetime
duration = $9750. CONCLUSION: In this model that examined
an intervention that had little apparent effect on life expectancy,
increasing control cost of illness increased incremental costs and
incremental cost-effectiveness ratios, and ultimately increased
the apparent cost-effectiveness of this preventive treatment.
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OBJECTIVE: The objective was to validate the construct of the
German-translated version of the Norfolk QOL-DN by factor
analysis in a German population with ﬁve stages of neuropathy
and correlate the resulting factors with degrees of neuropathy.
METHODS: Conducted in 97 sites in Germany, 186 patients
(type-1 n = 33; type-2 n = 153) with diabetic neuropathy were
assessed and categorized: asymptomatic DN (n = 40); sympto-
matic DN (n = 46); DN with history of foot ulcers (n = 32); DN
with amputations (n = 22); and DN with history of amputations
(n = 46). Data was assessed from completion of two self-
administered HQOL questionnaires: Short Form-12 (SF-12) and
Norfolk QOL-DN, a 47 item nerve ﬁber speciﬁc tool, back and
forward translated from English into German. Factor analysis by
Varimax rotation was performed; relationship of the factors to
stages of complications was conducted using two METHODS:
least squares regression and PLUM. Complication stage was
entered as the dependent variable, with all ﬁve factors as pre-
dictors. RESULTS: Five factors resulted from analysis of this
German neuropathy population (multi-staged), matching factors
from a European study population (mild neuropathy). The ﬁrst
factor (Functional Status/Large Fiber) and third factor Activities
